Last reviewed · How we verify
NCT05568966: NOVEL-2
Collection of Blood Samples for New Diagnostic Devices 2
NA trial testing Venous blood draw in Embolism and Thrombosis in 20,000 participants. Currently enrolling.
20 August 2026
Quick facts
| Lead sponsor | LumiraDx UK Limited |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20,000 |
| Start date | 11 July 2022 |
| Primary completion | 20 August 2026 |
| Estimated completion | 20 August 2026 |
| Sites | 7 locations across United Kingdom |
Drugs / interventions tested
- Venous blood draw
- Fingerstick
Conditions studied
- Embolism and Thrombosis — all drugs for Embolism and Thrombosis →
- Cardiovascular — all drugs for Cardiovascular →
- Renal — all drugs for Renal →
- Inflammation — all drugs for Inflammation →
Sponsor
LumiraDx UK Limited — full company profile →
Who can join
18 and older, any sex, with Embolism and Thrombosis or Cardiovascular. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To research and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that are comparable to the approved gold standard reference methods and will radically enhance clinicians and patients ability to monitor health conditions and improve outcomes by delivering the results near patient at the point of care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05568966
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Venous blood draw
Trials testing the same drug.
- NCT04042298 — Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy · completed
- NCT04074980 — Evaluation of the Accuracy of INR Results From Patients Taking Phenprocoumon as Anticoagulant When Measured Using the Lu · NA · completed
Other recruiting trials for Embolism and Thrombosis
Currently open trials in the same condition.
- NCT05853796 — Observational Dutch Young Symptomatic StrokE studY - nEXT · recruiting
- NCT04304651 — Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism · NA · recruiting
Other LumiraDx UK Limited trials
Trials by the same sponsor.
- NCT05787444 — Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory · unknown
- NCT05728970 — Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of Care (POC · completed
- NCT05506618 — Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test (ASPIRE-2) · NA · unknown
- NCT05403853 — A Performance Evaluation of the Lumiradx Point of Care HbA1c Device · NA · completed
- NCT05268939 — Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVI · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05568966 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LumiraDx UK Limited
- Last refreshed: 5 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05568966.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing